Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

被引：22
|
作者：
Paz-Ares, Luis G.
Ciuleanu, Tudor-Eliade
Lee, Jong-Seok
Urban, Laszlo
Caro, Reyes Bernabe
Park, Keunchil
Sakai, Hiroshi
Ohe, Yuichiro
Nishio, Makoto
Pluzanski, Adam
Ramalingam, Suresh S.
Brahmer, Julie R.
Borghaei, Hossein
O'Byrne, Kenneth John
Hellmann, Matthew D.
Memaj, Arteid
Bushong, Judith
Tran, Phuong
Reck, Martin
机构：
[1] Univ Complutense, CNIO H12o Lung Canc Clin Res Unit, Hosp Univ 12 Octubre, Madrid, Spain
[2] CiberOnc, Madrid, Spain
[3] Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania
[4] UMF Iuliu Hatieganu, Cluj Napoca, Romania
[5] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[6] Matrai Gyogyint, Matrahaza, Hungary
[7] Hosp Univ Virgen Del Rocio, Inst Biomed Seville, Seville, Spain
[8] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[9] Saitama Canc Ctr, Saitama, Japan
[10] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[11] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[12] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[14] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA
[15] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[16] Princess Alexandra Hosp, Brisbane, Qld, Australia
[17] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[18] Bristol Myers Squibb, Princeton, NJ USA
[19] Bristol Myers Squibb, Springfield, PA USA
[20] German Ctr Lung Res, LungClin, Airway Res Ctr North, Grosshansdorf, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9016
引用
收藏
页数：4
相关论文
共 50 条
  • [21] First-Line Nivolumab plus Ipilimumab (NIVO plus IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227
    Borghaei, H.
    Brahmer, J. R.
    Lee, J. -S.
    Ciuleanu, T. -E.
    Caro, R. Bernabe
    Nishio, M.
    Urban, L.
    Audigier-Valette, C.
    Lupinacci, L.
    Sangha, R.
    Paz-Ares, L. G.
    Reck, M.
    O'Byrne, K. John
    Gupta, R. G.
    Bushong, J.
    Li, L.
    Blum, S. I.
    Eccles, L.
    Ramalingam, S. S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E8 - E9
  • [22] Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
    Ramalingam, S. S.
    Balli, D.
    Ciuleanu, T-E.
    Pluzanski, A.
    Lee, J-S.
    Schenker, M.
    Caro, R. Bernabe
    Lee, K. H.
    Bartolucci, R.
    Audigier-Valette, C.
    Hellmann, M. D.
    Paz-Ares, L. G.
    Reck, M.
    Borghaei, H.
    Brahmer, J. R.
    O'Byrne, K.
    Tran, P.
    Spires, T.
    Geese, W. J.
    Agrawal, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1375 - S1376
  • [23] Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)
    Hellmann, M. D.
    Rizvi, N.
    Gettinger, S. N.
    Goldman, J.
    Chow, L. Q.
    Juergens, R.
    Borghaei, H.
    Brahmer, J.
    Shen, Y.
    Harbison, C. T.
    Nathan, F.
    Ready, N. E.
    Antonia, S. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S633
  • [24] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) vs chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): 3-year update from CheckMate 9LA
    Reinmuth, Niels
    Paz-Ares, Luis
    Ciuleanu, Tudor-Eliade
    Cobo-Dols, Manuel
    Bennouna, Jaafar
    Cheng, Ying
    Mizutani, Hideaki
    Lingua, Alejo
    Reyes, Felipe
    Menezes, Juliana
    Jassem, Jacek
    Protsenko, Svetlana
    Feeney, Kynan
    De la Mora Jimenez, Emmanuel
    Lu, Shun
    John, Thomas
    Carbone, David Paul
    Zhang, Xiaoqing
    Hu, Nan
    Reck, Martin
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 162 - 163
  • [25] Nivolumab plus ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.
    Ramalingam, Suresh S.
    Ciuleanu, Tudor Eliade
    Pluzanski, Adam
    Lee, Jong-Seok
    Schenker, Michael
    Caro, Reyes Bernabe
    Lee, Ki Hyeong
    Zurawski, Bogdan
    Audigier-Valette, Clarisse
    Provencio, Mariano
    Linardou, Helena
    Kim, Sang-We
    Borghaei, Hossein
    Hellmann, Matthew David
    O'Byrne, Kenneth John
    Paz-Ares, Luis G.
    Reck, Martin
    Nathan, Faith Ellen
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA
    Reck, M.
    Ciuleanu, T. -E.
    Cobo Dols, M.
    Schenker, M.
    Zurawski, B.
    Menezes, J.
    Richardet, E.
    Bennouna, J.
    Felip, E.
    Juan-Vidal, O.
    Alexandru, A.
    Sakai, H.
    Scherpereel, A.
    Lu, S.
    John, T.
    Carbone, D. P.
    Meadows-Shropshire, S.
    Yan, J.
    Paz-Ares, L. G.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 140 - 140
  • [27] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
    Chau, Ian
    Ajani, Jaffer A.
    Doki, Yuichiro
    Xu, Jianming
    Wyrwicz, Lucjan
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez Freitas Melro
    Holtved, Eva
    Murphy, Mariela A. Blum
    Abdullaev, Sandzhar
    Soleymani, Samira
    Lei, Ming
    Kato, Ken
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Nivolumab (NIVO) plus ipilimumab (IPI)+2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA
    Reck, M.
    Ciuleanu, T. -E.
    Dols, M. C.
    Schenker, M.
    Zurawski, B.
    Menezes, J.
    Richardet, E.
    Bennouna, J.
    Felip, E.
    Vidal, O. J.
    Alexandru, A.
    Sakai, H.
    Scherpereel, A.
    Lu, S.
    John, T.
    Carbone, D. P.
    Meadows-Shropshire, S.
    Yan, J.
    Paz-Ares, L. G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S2 - S2
  • [29] Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
    Reck, Martin
    Ciuleanu, Tudor-Eliade
    Dols, Manuel Cobo
    Schenker, Michael
    Zurawski, Bogdan
    Menezes, Juliana
    Richardet, Eduardo
    Bennouna, Jaafar
    Felip, Enriqueta
    Juan-Vidal, Oscar
    Alexandru, Aurella
    Sakai, Hiroshi
    Scherpereel, Arnaud
    Lu, Shun
    John, Thomas
    Carbone, David Paul
    Meadows-Shropshire, Stephanie
    Yan, Jinchun
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227-part 2 final analysis
    Paz-Ares, L.
    Ciuleanu, T. E.
    Yu, X.
    Salman, P.
    Pluzanski, A.
    Nagrial, A.
    Havel, L.
    Kowalyszyn, R.
    Audigier-Valette, C.
    Wu, Y-L.
    Borghaei, H.
    Hellmann, M. D.
    Brahmer, J.
    Reck, M.
    Ramalingam, S.
    Zhang, L.
    Bhagavatheeswaran, P.
    Nathan, F. E.
    O'Byrne, K. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 67 - 68
12345